Chimeric antigen receptor T-cell therapies using defined product compositions require high-purity T-cell isolation systems that, unlike immunomagnetic positive enrichment, are inexpensive and leave no trace on the final cell product. Here, we show that DNA aptamers (generated with a modified cell−SELEX procedure to display low-nanomolar affinity for the T-cell marker CD8) enable the traceless isolation of pure CD8 + T cells at low cost and high yield. Captured CD8 + T cells are released label-free by complementary oligonucleotides that undergo toehold-mediated strand displacement with the aptamer. We also show that chimeric antigen receptor T cells manufactured from these cells are comparable to antibody-isolated chimeric antigen receptor T cells in proliferation, phenotype, effector function and antitumour activity in a mouse model of B-cell lymphoma. By employing multiple aptamers and the corresponding complementary oligonucleotides, aptamer-mediated cell selection could enable the fully synthetic, sequential and traceless isolation of desired lymphocyte subsets from a single system.
T he clinical impact of T-cell therapies is being rapidly realized with two recent FDA approvals for chimeric antigen receptor (CAR) T-cell therapies treating acute lymphoblastic leukaemia and diffuse large B-cell lymphoma (Novartis's Kymriah and Gilead−Kite's Yescarta, respectively), as well as many promising results in clinical trials [1] [2] [3] [4] . CAR T cells have also been generated as potential anti-HIV therapies 5, 6 . The production and administration of autologous CAR T-cell therapy involves harvesting and genetically manipulating T cells before reintroducing the engineered cells back into the patients. The first step in this process, cell harvesting, requires high-purity isolation of the desired cell populations. For example, CAR T cells with defined 1:1 CD4 + to CD8 + cell populations have been reported to be more potent than CD4 + or CD8 + cells alone, or unselected populations in animal models of leukaemia, and are also very effective in human clinical trials for acute lymphoblastic leukaemia 7, 8 .
T cells for CAR T-cell manufacturing are typically isolated from peripheral blood mononuclear cells (PBMCs) collected by leukapheresis. One method reported for use in clinical-scale T-cell isolation is the sequential isolation of CD8 + and CD4 + T cells from the apheresis product by immunomagnetic positive enrichment (CliniMACS, for example) 9 . This approach can achieve high purity and yield but may suffer from: high costs associated with biologically produced antibodies; potential safety concerns stemming from a final cell population that may still be associated with antibodycoated magnetic beads; and low throughput due to the need for multiple selection apparatuses in sequence 10 . Furthermore, the magnetic beads retained on the cells may prevent the downstream selection of cell subsets that could be beneficial for therapy. Although clinical selection strategies that immunodeplete undesired cell populations allow for the isolation of untouched cells and downstream positive selection of specific cell subsets, they also: introduce more costs by relying on a large panel of antibodies for depletion; reduce the yield by half as the apheresis product has to be split to obtain separate subsets of both CD4 + and CD8 + T cells; and may result in target cells with a low purity 11, 12 .
Streptamer-based cell-selection technology that avoids some of these undesirable outcomes through fragment antigen-binding constructs (Fabs) fused with peptide tags that bind reversibly to magnetic beads coated with engineered streptavidin has been reported [13] [14] [15] . Fabs can be released from the beads as a result of competition with high-affinity d-biotin and therefore must be engineered with relatively low receptor-binding affinity so that they dissociate rapidly from the cell once released in the monovalent form [14] [15] [16] [17] . While the extent of Fab internalization into the cells after release from the solid support is unclear, Fabs engineered with relatively low receptor binding are not substantially retained on the cell surface 16 . However, this method is still costly due to its reliance on biologically produced engineered streptavidin and modified Fabs. Additionally, all the aforementioned approaches have low throughput and high supply requirements for CD4 + and CD8 + T-cell isolation and rely on multiple selection apparatus either in sequence or in parallel. Thus, despite technological advances in cell selection, an overall approach that has low cost, traceless selection and high throughput while maintaining a reasonable yield and purity has remained elusive (Supplementary Table 1 ).
Nucleic acid aptamers (single-stranded oligonucleotides capable of binding target molecules) are an attractive alternative to antibodies and Fabs for cell selection. First developed in the 1990s [18] [19] [20] , aptamers can possess binding affinities comparable to (or even higher than) antibodies. Importantly, aptamers are produced synthetically as well-defined, low-variability products with a long storage stability, making them inexpensive and easy to manufacture [21] [22] [23] . Aptamers are commonly discovered through a library selection method known as systematic evolution of ligands by exponential enrichment (SELEX) and can be further optimized for chemical stability. With their favourable attributes, as summarized in Supplementary Table  1 , the application field for aptamers has escalated in the last quarter Articles Nature Biomedical eNgiNeeriNg of a century to encompass areas including sensing, purification, diagnostics, drug delivery and therapeutics 24 .
Here, we report a reversible aptamer-selection technology for the isolation of label-free CD8 + T cells. Three main facets of the work are presented. First, we identified several high-affinity DNA aptamers specific for CD8 using a modified cell−SELEX procedure and validated the binding characteristics of selected aptamers. We compared magnetic-activated cell sorting (MACS) with one of the aptamers to the antibody-based CD8 Microbead system that is used clinically and found that the aptamer isolated CD8 + T cells from PBMCs with efficiencies comparable to the standard method. Second, we developed a method to reverse aptamer binding using a complementary oligonucleotide reversal agent to disrupt aptamer folding. We show that CD8 + cells can be released from aptamer-immobilized supports with high yield and purity using this approach. Finally, we generated and fully characterized CAR T cells from both our reversible aptamer selection approach and standard, antibody-based selection. CAR T cells isolated using traceless aptamer selection were phenotypically similar to those isolated using antibodies and exhibited nearly identical effector functions, both in vitro and in vivo. This aptamer-based selection approach therefore enables highly efficient, label-free and inexpensive selection of T cells for potential clinical-scale cell therapy applications. With the future discovery of other T-cell-specific aptamers, such as a CD4 aptamer, this technique could be readily expanded for high-throughput, serial selection of multiple T-cell populations from a single apparatus using a panel of aptamers and corresponding reversal agents.
results

Identification of T-cell-binding aptamers by cell−SELEX incorporating competitive and counter selection.
The generation of highly specific aptamers is critical for cell isolation applications. As our initial efforts to identify T-cell-specific aptamers using either traditional protein−SELEX with recombinant proteins or cell− SELEX 25, 26 with engineered cell lines were unsuccessful and yielded aptamers with poor specificity, we hypothesized that both the native display of receptors on cell surfaces afforded by cell−SELEX and the increased stringency of selection provided by competitive selection 27 would be required to discover a T-cell-specific aptamer. We therefore modified the published cell−SELEX protocol 28 to include both competitive selection (selection in the presence of relevant undesired cells) and counter selection (the depletion of aptamers binding undesired targets) ( Fig. 1 ). After an initial round of positive selection against T cells using a single-stranded DNA library with a 52 base pair (bp) random region (10 16 variants), the selected aptamer pool underwent multiple rounds of competitive/counter selection. Each round included the competitive selection of T-cellbinding aptamers, which was achieved by incubating aptamer pools with PBMCs and then isolating untouched T cells and extracting the bound aptamers. Collected aptamers were then subjected to counter selection by incubation with J.RT3-T3.5, a CD3 − CD4 lo CD8 − human T-cell leukaemia line, to remove aptamers binding non-selective surface proteins expressed on T cells. Selection stringency in each of five selection rounds was increased as summarized in Supplementary Table 2 and selection progress was monitored by flow cytometry ( Supplementary Fig. 1 ). Binding to a subset of T cells was observed by round 3 and increased in rounds 4 and 5. Selection was halted after five rounds due to the non-specific binding to counter-selection cells observed in round 5.
Aptamer pools from each round of selection were identified by next generation sequencing (NGS) using the primers detailed in Supplementary Table 3 and analysed using FASTAptamer 29 . Phylogenetic trees of the top 100 aptamers were generated using FigTree 30 and consensus motifs identified using MEME analysis 31 ( Supplementary Fig. 2 ). Aptamer sequences collapsed in round 4 to two major branches with two overlapping motifs (Motifs 1 and 2).
In round 5, a new motif, Motif 3, emerged, as well as Motif 4, which overlaps with Motif 1. Supplementary Table 4 shows the top 20 aptamers identified from round 5 in order of prevalence, the predicted motif and the enrichment of each aptamer in successive rounds.
Five aptamers (named according to their rank in Supplementary  Table 4 and listed in Supplementary Table 5 ) were selected for binding studies with primary T cells and counter selection with J.RT3-T3.5 cells on the basis of on their abundance, motif, enrichment between rounds, family representation on the phylogenetic tree and the low energy state of their secondary structure ( Supplementary Fig. 3 ). Fluorescein-labelled aptamers A1, A3 and A8 displayed specific binding to a subset of mixed T cells whereas A2 and A7 exhibited whole-population binding to both T cells and J.RT3-T3.5 cells, compared to a randomly chosen aptamer from the naive library (RN) ( Supplementary Fig. 4 ). Interestingly, A2 and A7, but not A1, A3 or A8, belong to the unique Motif 3 that emerged in round 5 and showed significant enrichment (>100-fold) between rounds 4 and 5 when non-specific binding to J.RT3-T3.5 cells in the bulk aptamer pool was observed.
Characterization of T-cell-binding aptamers.
We hypothesized that aptamers A1, A3 and A8 probably bind to the same receptor due to their overlapping motifs. Furthermore, we suspected that the aptamers bind to CD8 as this protein is not expressed on the counter-selection cell line and CD8:CD4 T-cell ratios are low in healthy donor pan-T-cell isolates, consistent with the 20-30% binding observed in the mixed T-cell population ( Supplementary Fig. 4 ). We therefore analysed aptamer binding to mixed human T cells with CD4 and CD8 antibody labelling and demonstrated that all three aptamers bind to CD8 + but not CD4 + T cells, suggesting that aptamers bind to human CD8 ( Fig. 2a ). A similar binding study against murine splenocytes did not, however, show any binding to the T-lymphocyte subset, suggesting that the aptamers, like antihuman CD8 antibodies, do not bind murine CD8 ( Supplementary Fig. 5a ). Aptamers A1, A3 and A8, however, do bind to CD8 + T cells in rhesus macaque PBMCs, which is consistent with the rhesus crossreactivity observed in many antihuman CD8 antibody clones ( Supplementary Fig. 5b ). We confirmed that these aptamers bind the human CD8 alpha chain isoform (CD8a) expressed on cells using three techniques: competitive binding with a CD8-specific antibody; short interfering RNA (siRNA) knockdown of CD8a in T cells; and enforced CD8a expression in CD8 − cells. Increasing concentrations of an unlabelled CD8-specific antibody (clone RPA-T8), but not a CD3-specific antibody, robustly outcompeted all three aptamers for binding to CD8 + T cells during a coincubation ( Supplementary Fig. 6 ). CD8a knockdown (75%) by siRNA ( Supplementary Table 6 ) in primary CD8 + T cells was confirmed by antibody staining and correlated with a 73-77% reduction in the binding of all three aptamers ( Fig. 2b ). Transient expression of CD8a from a green fluorescent protein (GFP) reporter plasmid in CD8 − Jurkat immortalized human lymphocyte cells introduced aptamer binding specifically to GFP + cells ( Fig. 2c ).
To validate aptamer binding to the CD8a protein itself, we measured association and dissociation kinetics by biolayer interferometry (BLI), in which a serial dilution of recombinant extracellular CD8a protein (Ser22-Asp182) was screened against aptamers immobilized on streptavidin-coated BLI sensors. Whereas the RN aptamer negative control exhibited no detectable association with the CD8a protein (data not shown), the A1, A3 and A8 aptamers bound the protein with binding affinities (K D values) of 20.1 ± 0.2, 14.7 ± 0.1 and 5.59 ± 0.11 nM, respectively ( Fig. 2d and Supplementary Table 7 ). Interestingly, the A3 aptamer had both the highest association (K on ) and dissociation (K dis ) rate constants of the three aptamers, whereas A8 had the lowest K dis . We also evaluated the apparent K D values of aptamer binding to CD8 + T cells by Articles Nature Biomedical eNgiNeeriNg flow cytometry, and the A1, A3 and A8 aptamers have apparent K D values of 18.3 ± 4.6, 1.9 ± 0.8 and 2.4 ± 0.9 nM, respectively ( Fig. 2e ). The observed differences in K D values determined by the two methods were expected. Mass transport limitations not present with BLI but present when staining cells in static wells favour re-binding and thereby limit dissociation, improving the apparent K D of the faster-dissociating A3 relative to the other aptamers. Furthermore, at saturating concentrations of aptamer, where binding advantages stemming from high K on values are diminished given enough time (that is, binding at or near steady-state), the A8 aptamer displays increased binding over A3, consistent with the large difference in K dis between the two aptamers. Regardless, all three aptamers have a high binding affinity to CD8a protein and CD8 + T cells, with K D values comparable to monoclonal antibodies.
Reversing aptamer binding with a complementary oligonucleotide. To achieve traceless cell isolation using an aptamer-based affinity agent, a method to reverse aptamer binding to the cell is needed in the cell recovery step. Aptamer binding can be disrupted by nuclease-mediated degradation of the aptamer 32, 33 , applied force 34 , competitive binding 35 or denaturing the secondary structure, either through heat 36 or complementary oligonucleotide binding [37] [38] [39] [40] . Of these methods, complementary oligonucleotide displacement is a preferred approach due to its advantages of being gentle (compared to heat or force), with a high yield (compared to competitive binding) and relatively low cost (compared to nuclease degradation). We therefore designed a CD8-binding aptamer that could be released from cells by binding with a complementary displacement strand (reversal agent).
Two major considerations in the design of the selection aptamer and reversal agent are: high-affinity binding to target cells by the selection aptamer; and rapid disruption of the aptamer secondary structure, which is critical for receptor binding by the rever-sal agent. We therefore chose the A3 aptamer for cell selection, not only due to its low apparent K D for CD8 + T cells, but also because of its high K on and K dis for CD8a protein. As multivalent display of the aptamer on a selection medium would potentially mitigate passive cell dissociation, because there are aptamers in cis to retain cell binding even if a few aptamers dissociate, we rationalized that faster association kinetics would probably be more important for cell isolation. Furthermore, a high K dis implies less stable binding, suggesting that strategies to reverse aptamer binding by complementary oligonucleotide displacement may be more successful. We also tested a reported CD8 aptamer from the literature 41, 42 ; however, low binding was observed under the binding conditions in the published research and our study ( Supplementary Fig. 7 ). A toehold region was then extended on the 3′ end of the original A3 sequence (A3t) to facilitate the initiation of cell release by the complementary reversal agent ( Fig. 3a and Supplementary Table 5 ). Toeholds are single-strand sequences that allow for complementary sequence binding and the supplanting of prepaired bases through a method known as strand displacement [43] [44] [45] [46] [47] . In this case, the reversal agent would undergo strand displacement via the toehold to abrogate intrastrand base pairing in the aptamer necessary for its secondary structure. It has been previously described that the rate constant of strand displacement depends critically on the toehold length, varying over up to six orders of magnitude, with maximum rates reached with toeholds over six bases in length 47 ; an octanucleotide toehold was therefore used in our CD8-aptamer selection agent. The reversal agent was designed to be 36 bases in length based on the predicted change in secondary structure on binding ( Fig. 3b and Supplementary Table 5 ).
We demonstrated effective and rapid aptamer release from cells by the reversal agent using a fluorescently labelled aptamer with flow cytometry analysis. To determine the appropriate conditions for release, various concentrations of reversal agent (ranging from 10 -1 10 -1 10 3 10 2 10 1 10 0 10 -1 10 3 10 2 10 1 10 0 10 2 10 1 10 0 10 2 10 1 10 0 10 2 10 1 10 0 10 2 10 1 10 0 10 2 10 3 10 1 10 0 10 -1 10 3 10 2 10 1 10 0 10 -1 
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Nature Biomedical eNgiNeeriNg 25 -to 100-fold excess), temperatures (4 °C, room temperature and 37 °C) and times of incubation (5, 10 and 20 min) were evaluated ( Supplementary Fig. 8 ). While >70% A3t aptamer release was observed in all conditions, 90% release could be achieved with just a 10 min incubation at room temperature with 100-fold excess reversal agent. We therefore chose these parameters for our label-free isolation strategy.
An aptamer-based strategy for traceless T-cell isolation.
Before applying the A3t aptamer to a cell selection process, it was imperative to ensure that the aptamer selectively binds T cells when other types of PBMCs are present. At the concentration used for cell isolation (5 nM), minimal binding to CD3 − CD56 − CD14 + monocytes and CD3 − CD56 − CD19 + B cells was observed and binding to these cell populations was not above the RN aptamer control ( Supplementary  Fig. 9 ). Binding to B cells was especially low (close to 0%)-a desirable trait given that the transduction of a single, highly competent leukaemic B cell with a CAR was recently shown to induce resistance to therapy 48 . In addition to CD3 + CD56 − T cells, the A3t aptamer displayed substantial binding to CD3 + CD56 + natural killer T (NKT) cells and CD3 − CD56 + natural killer (NK) cells (as expected), which are known to have subsets that express CD8. As NKT cells have been found to improve CAR T-cell therapy 49 , binding to these cells was seen as beneficial. Importantly, the median fluorescent intensity (MFI) of aptamer binding on A3t-positive monocytes, B cells and NK cells is much lower compared to that of A3t-positive T and NKT cells, suggesting that binding events would minimally capture the contaminant cells at this aptamer concentration. We predicted that the selection aptamer A3t and its cognate reversal agent could be used to achieve traceless T-cell isolation in a completely synthetic system in which immobilized aptamers are used to isolate T cells that are then released by the addition of the reversal agent, which disrupts the secondary structure of the aptamer that is critical for binding ( Fig. 4a ). We tested this strategy using the A3t aptamer immobilized on immunomagnetic Anti-Biotin Microbeads (Miltenyi Biotec). We compared the aptamer strategy to antibody-based CD8 Microbeads (Miltenyi Biotec) in terms of their abilities to isolate CD8 + T cells with high purity and yield from three healthy donor PBMC populations, as CD8 Microbeads are the only selection technology approved for clinical-scale CAR T-cell manufacture at present. PBMCs were incubated with functionalized beads and applied onto a column under a magnetic field, after which the flow-through fraction was collected. Antibody-isolated cells were then removed from the column using a column flush whereas aptamer-isolated cells were exposed to a 100-fold excess of reversal agent for 10 min on the column. The column was then unplugged and washed, which constituted the reversal agent elution (RAE) fraction. Any remaining cells on the column were removed using a column flush. The fractions of both isolation methods were analysed via flow cytometry ( Supplementary Fig. 10 )
We observed near-complete depletion of CD8 + cells from the flow-through fraction using aptamer-loaded microbeads, comparable to that obtained using antibody-based CD8 Microbeads. This corresponded to the enrichment of CD8 + cells in the RAE and column flush fractions ( Fig. 4b ). Further analysis of the CD8 + cells in the RAE fraction showed that these cells were predominantly CD3 + CD16 − T cells (>97%), with only a small fraction of the population being CD8 lo CD16 + monocytes and NK cells ( Fig. 4c ). Importantly, this purity analysis is conservative, as it does not account for CD3 + CD16 + NKT cells. On average, the combined RAE and column flush of the aptamer-based isolation yielded 97.5% of the CD8 + T cells from the starting PBMC population (comparable to that obtained from antibody-based isolation) and the traceless isolation alone (RAE fraction) yielded 72.3% (Fig. 4d ). Even if contaminating CD8 − cells are included, the average purity of CD8 + T cells in the RAE fraction was 95.6%, illustrating that the A3t aptamer displays minimal non-specific binding to CD8 − cells in PBMCs (Fig. 4e ). The CD8 staining of aptamer-isolated CD8 + T cells in the RAE fraction with the RPA-T8 antibody clone was comparable to that of CD8 + T cells in the starting PBMC population, whereas that of antibody-isolated CD8 + T cells was lower ( Fig. 4f) . Given that the antibody-based method depletes nearly the whole CD8 + T-cell population (Fig. 4b,d ), the lower CD8 staining is probably a result of the cell-bound CD8 Microbeads hindering the binding of the staining antibody clone used (Fig. 4f ). This further emphasizes certain advantages of the traceless nature of reversal agent strand displacement, which can enable accurate, downstream phenotyping of capture antigens without needing to optimize the staining antibody clone. Interestingly, aptamer-isolated CD8 + T cells in the column flush fraction that were not stripped off in the RAE were just as pure as those in the RAE fraction ( Fig. 4e ). However, they also had higher CD8 expression than those in the RAE fraction ( Fig. 4f ), albeit not significantly so, indicating that cells with higher CD8 expression and thus aptamer-bead labelling may be more difficult to remove from the column by RAE. Although simply flushing the column would provide a similarly pure product with higher yield than using a reversal agent, RAE allows the isolation of cells free of magnetic beads in a manner that is specific to each selection aptamer used. In addition to providing traceless cell recovery, this approach affords the potential for both further downstream selection of different cell subsets and the serial selection of different cell types from a single selection process.
To confirm that aptamer-isolated cells are similar to antibodyisolated cells, we compared the CD8 + T cells in the RAE fraction of the aptamer-based isolation to those of the antibody-based isolation using flow cytometry phenotyping and NanoString nCounter transcript profiling. Whereas CD8 + T cells in the aptamer-isolated RAE fraction were phenotypically identical to those in PBMCs, antibody-isolated CD8 + T cells comprised a slightly larger percentage of cells in a transitional stage of dual CD45RA/RO expression that coincided with a small reduction in effector memory cells ( Supplementary Fig. 11a ). Transcriptionally, however, aptamer-and antibody-isolated cells were identical ( Supplementary Fig. 11b ). No gene transcripts were differentially expressed in significantly higher or lower amounts, suggesting that there are no immediate side effects to briefly exposing the cells to high reversal agent concentrations. 
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Generation of CAR T cells from aptamer-based traceless cell isolates. Few differences were observed between aptamer-and antibody-isolated cells immediately after isolation and we sought to confirm whether this would stay true for a final CAR T-cell product generated using these different isolation methods. We thus generated CD8 + CAR T cells from both the antibody-isolated cells and the traceless aptamer-isolated cells (RAE fraction) shown in Fig.  4d -f and fully compared their outgrowth, phenotype, gene expression and effector function. Antibody-isolated CD4 + T cells were not included in these studies so as not to convolute any differences between the CD8 + T cells isolated from the different methods. We transduced cells with the PLAT-02 lentiviral vector, which encodes a second generation CD19scFv-41BB-CD3ζ CAR (and the truncated version of the epidermal growth factor receptor, EGFRt, as a surrogate transduction marker) that is used in ongoing clinical trials ( Fig. 5a ) 9 . CD19 CAR T cells were manufactured using a sequential two week stimulation bead outgrowth from days S1D0 to S1D14 and a two week rapid expansion protocol (REP) with irradiated CD19 + feeder cells from days S1R1D0 to S1R1D14, as summarized in Supplementary Fig. 12 , where S1 denotes the bead stimulation, R1 indicates the REP and D# signifies the number of days since stimulation or REP onset. After transduction, high expression of the surrogate transduction marker EGFRt (>60%) was observed on S1D9 without additional selection and was further increased using immunomagnetic enrichment and over the REP period to at least 94% on S1R1D13 before functional assays were run (Fig. 5b) . Importantly, although transduction copy number was probably variable, given the variation in surrogate transduction marker expression, there was no difference in the mean EGFRt MFI between antibody-and aptamer-isolated cells (Fig. 5b) .
Over the two week stimulation period, we observed no differences in the outgrowth between untransduced antibody-and aptamer-isolated mock T cells (Fig. 5c ). This was consistent with the similar Ki-67 expression between both mocks and CD19 CAR T cells from the different isolation methods at the end of the two week stimulation outgrowth ( Fig. 5d ) and unsurprisingly the cells grew identically during the REP ( Supplementary Fig. 13 ). On S1D14, while staining for PD1, TIM3 and LAG3 coexpression (markers of both activation and exhaustion) we observed small differences in the accumulation of these markers between cells from the different isolation methods at the end of the two week stimulation outgrowth ( Fig. 5e and Supplementary Fig. 14) . Whereas aptamer-isolated CD19 CAR T cells had a loss of TIM3 + PD1 − TIM3 − cells and a gain of PD1 + TIM3 + cells compared to antibody-isolated cells, opposite trends were seen in the mock cells between the two isolation methods, suggesting that these differences are probably artefacts of transduction and the stimulation process and not the isolation strategy. Consistent with the exhaustion/activation data, aptamer-isolated CD19 CAR T cells from the same day exhibited more differentiation than the antibody-isolated cells, as indicated by the greater proportion of CD45RA − CD62L + , but the mock cells of the two isolation methods were equivalently differentiated ( Fig. 5f  (left) and Supplementary Fig. 15 ). However, after a two week REP process, the aptamer-isolated CD19 CAR T cells were less terminally differentiated than the antibody-isolated cells while the mocks remained the same, again suggesting that the isolation strategy is not the principal cause of these small differences ( Fig. 5f (right) and Supplementary Fig. 15 ). NanoString nCounter transcript profiling of immune-associated genes further confirmed that there were minimal differences between the two isolation methods with zero genes being differentially expressed in significantly higher or lower amounts between aptamer-and antibody-isolated mock and CD19 CAR T cells at the end of the REP before functional testing ( Supplementary Fig. 16 ). These results reaffirm that the aptamer selection strategy did not have any durable, long-term side effects on CAR T-cell fitness.
We evaluated the antitumour effector function of these cells against both myelogenous leukaemia K562 cells lines that were transduced to stably express OKT3 Fab and CD19 for CD3 and CAR engagement, respectively, as well as B lymphoma Raji cells that constitutively express moderate levels of CD19 ( Supplementary  Fig. 17 ). On tumour challenge in vitro, aptamer-isolated CD19 CAR T cells lysed all three cell types to similar extents to antibody-isolated cells and secreted identical amounts of the effector cytokines tumour necrosis factor (TNF)-α and interferon (IFN)-γ (Fig. 5g,h) . Thus, CAR T cells derived from an aptamer-based traceless isolation strategy perform in vitro to the standard of cells derived from the widely used antibody-based isolation.
Aptamer-isolated CAR T-cell performance in systemic Raji tumour mouse model. In vitro cytotoxicity results with CAR T cells do not always corroborate with in vivo results 50 . Thus, despite observing little difference in the effector function of antibody-and aptamerisolated CD8 + CAR T cells in vitro, it was important to further show that this would translate in vivo. To this end, we used a less stringent version of the previously described CAR T-cell stress test 50, 51 , in which Raji-bearing NOD/SCID/IL-2R-γ null (NSG) mice were treated with a non-curative dose of CD8 + CD19 CAR T cells from the different isolation methods at the end of the REP (S1R1D14). Mice were injected with 5 × 10 5 GFP-ffluc CD19 + Raji cells and treated 7 d later with 10 7 antibody-or aptamer-isolated S1R1D14 CD8 + CAR T cells, as previously described 52 . CD8 + mock T cells from both isolation methods were included as placebo controls.
Administration of 2 × 10 7 CD8 + CAR T cells was previously shown to be only 50% curative long term with this model due to the absence of the CD4 + CAR T-cell subset critical for therapy persistance 52 . The CD8 + CAR T cells in this study were also expanded by both a two week bead stimulation and two week REP, and thus displayed markedly more exhaustion and differentiation than the one or two week expanded CAR T cells described in other publications 50, 51 . Consequently, using only 10 7 CD8 + CD19 CAR T cells in the same model was found to be non-curative with a maximal survival of approximately ten weeks (A. Johnson, unpublished observations). We therefore postulated that this T-cell stress study design would be able to rigorously identify any differences in antitumour effector function between antibody-and aptamer-isolated CAR T cells. Even so, in vivo, we continued to observe identical antitumour activity between both antibody-and aptamer-isolated CD8 + CAR T cells. Tumour regression and relapse kinetics, as measured using the photon flux of the tumour, overlapped between mice that received CAR T cells derived from the different isolation methods across multiple donors. (Fig. 6a ). Although the therapy was non-curative for both CAR T-cell treatment groups, indicative of a successful stress test model, mice receiving aptamer-isolated CAR T cells exhibited similar prolonged survival compared to mice receiving antibody-isolated CAR T cells as determined by both biological significance (median survival time) and log-rank statistical significance (Fig. 6b ). These results further illustrate that traceless aptamer-based cell isolation with strand displacement is a viable replacement for antibody-based isolation in the initial production step of CAR T-cell therapy, having negligible downstream impact on the quality of the final cell product.
Discussion
A challenge with CAR T-cell therapy is the time and cost associated with manufacturing a clinical product. As recent literature has shown that the selection of different T-cell subsets for therapy may provide improved and consistent clinical outcomes compared to undefined products starting from heterogenous PBMCs, it is increasingly imperative that efficient and cost-effective selection approaches are developed to meet the demands of these new therapeutic compositions 7, 8 . At present, CD8 + and CD4 + T cells are 
Fig. 5 | Characterization of CD19 Car T cells generated from antibody-and aptamer-isolated cells. a, The second generation CD19 CAR T-cell construct with
EGFRt reporter that was used to retrovirally transduce isolated T cells. b, Left, flow cytometry analysis of EGFRt expression in antibody-and aptamer-isolated T cells 9 d after initial bead stimulation (S1D9) and 13 d after the REP (S1R1D13) with irradiated CD19 + TM-LCL cells. The timeline for cell expansion is shown in Supplementary Fig. 12 . The flow graphs represent one independent experiment. Right, a chart indicating EGFRt reporter MFI at S1R1D13, using the symbols from . e, Flow cytometry analysis of PD1/TIM3/LAG3 expression in mock and CD19 CAR T cells on S1D14 immediately before the REP. Individual donor values can be found in Supplementary Fig. 14. The pie charts show the mean phenotype of the cells; n = 3 biologically independent samples; P > 0.05, *P < 0.05 and **P < 0.01 (paired two-way ANOVA with Bonferroni correction). f, Flow cytometry analysis of CD62L/CD45RA expression in mock and CD19 CAR T cells on S1D14 immediately before the REP and on S1R1D14 immediately before the functional assays. Individual donor values can be found in Supplementary Fig. 15 . The pie charts show the mean phenotype of the cells; n = 3 biologically independent samples; P > 0.05 and *P < 0.05 (paired two-way ANOVA with Bonferroni correction). g,h, In vitro antitumour cytotoxicity and cytokine release of mock and CD19 CAR T cells. For h, the symbols are as in Fig. 4d-f . Data points and error bars (g) and graph bars and error bars (h) represent the mean ± s.d.; n = 3 biologically independent samples; P > 0.05 (paired two-way ANOVA with Bonferroni correction (g); paired two-way ANOVA with Sidak correction (h)). SA-PE, streptavidin-phycoerythrin; PE-Cy7, phycoerythrin: cyanine-7 tandem conjugate.
Articles Nature Biomedical eNgiNeeriNg selected by either: splitting the starting leukapheresis product and immunomagnetically depleting undesired cells for further downstream positive selections; or sequential isolation from the leukapheresis product using immunomagnetic positive selections. Both approaches are far from perfect: the former wastes a portion of the cells in the starting population by splitting the cells, but saves time with parallel isolations; the latter is time consuming as it uses the whole population in each step. Furthermore, labels remaining on the cells prevent further selection and present regulatory barriers for clinical translation into patients. Two recent reports have used DNA-labelled antibodies followed by strand displacement to isolate multiple cell populations; however, antibodies and DNA tags remain attached to selected cells 53, 54 . The advent of Streptamer technology and similar avidity-reliant Fab multimerization strategies have partially mitigated these issues by enabling label-free isolation; however, these approaches still rely on expensive, biologically produced selection agents and require two or more apparatus in sequence to isolate pure, separate cell subsets 16, 17 . These technologies are also perishable and frequently have a sole supplier of consumables, which adds supply-chain risk to a cell therapy manufacturing process that is often time-sensitive for patients with refractory disease 10 . DNA aptamers and complementary strand displacement with a reversal agent present a unique opportunity to improve the selection of T cells for use in adoptive cell therapy. Aptamers are synthetic and thereby inexpensive to produce at large scales. Furthermore, their manufacture can be outsourced to one of many available companies and they have a long-shelf life, so they bear minimal supply-chain risk. High-affinity DNA aptamers can be developed against multiple targets and their sequences can be further modified after SELEX to include unique toeholds and stems for aptamer-specific strand displacement. Thus, panels of aptamers against diverse T-cell antigens can be developed with corresponding unique reversal agents for sequential label-free isolation of different cell subsets off the same column. As an example, microbeads loaded with CD4 and CD8 aptamers that have unique toeholds and sequences could be added at the same time to one whole leukapheresis product, and CD4 + and CD8 + T cells could be serially eluted off one column by sequential incubations with the corresponding reversal agents. A similar outcome can be achieved using a CD3 aptamer in combination with either a CD4 or CD8 aptamer. Alternatively, one could deplete CD8 + T cells and other unwanted cell subsets using a CD8-specific aptamer and other aptamers that bind monocytes, B cells and NK cells, respectively. Untouched CD4 + T cells could then be enriched in the flow-through fraction and CD8 + T cells could be selectively eluted from the column using a reversal agent specific to the CD8 aptamer. The key to executing these strategies is the identification of highly cell-specific aptamers.
In this study, we report the discovery of high-affinity CD8aspecific aptamers and the successful application of one aptamer with a reversal agent in a traceless CD8 + T-cell isolation system. Using the aptamer alone, we report an equivalent CD8 + T-cell selection yield compared to a widely used antibody-based approach. With a reversal agent for label-free elution, we observed a >70% selection yield and >95% purity of CD8 + T cells. Given that a 350-450 ml apheresis product from a person with acute lymphoblastic leukaemia will have 3-9 × 10 9 T cells, and only 200-600 × 10 6 CD8 + T cells are needed to manufacture a 1:1 CD4 + :CD8 + CAR T-cell therapy, the trade of lower yield for high purity, lower cost and label-free selection with this approach has little consequence but many benefits. Importantly, on the basis of anecdotal observations of the maximal capacity of this system at a small scale, we estimate that only US$5−10 of aptamer would be needed for reliable clinical-scale Articles Nature Biomedical eNgiNeeriNg isolation. CD19-directed CAR T cells manufactured from label-free, aptamer-isolated cells also exhibited identical performance to CAR T cells generated from antibody-selected cells in assays designed to measure antitumour effector function, showing that aptamerbased traceless cell isolation is a practical selection strategy for CAR T-cell therapy. Although the competitive SELEX approach was designed to identify multiple T-cell-specific aptamers, only CD8-specific aptamers were discovered with this strategy. We speculate that this occurred due to the strong partitioning of the library towards the high-affinity CD8 aptamers. SELEX strategies using untouched CD4 + primary T cells or the CD8 − Jurkat T-cell line may thus be required to identify aptamers that bind to alternative T-cell antigens like CD3 or CD4. Furthermore, due to the limited binding chemistry available to unmodified DNA aptamers, certain proteins may not be amenable to high-affinity aptamer discovery using unmodified DNA libraries. For these targets, increased chemical diversity including one or two modified base pairs in the library design may be needed for the successful partitioning of high-affinity binders 55 .
Fig. 6 | Tumour stress test with antibody-and aptamer-isolated CD8
In the future, aptamers could be readily functionalized for attachment to solid supports for affinity chromatography separation, thus resulting in a purely synthetic isolation system without the need for recombinant proteins, magnetic supports and pre-incubation with selection agents. Cell-release efficiency could be potentially improved, for example by refining the strand displacement kinetics between aptamer and reversal agent through further sequence optimization (higher toehold GC content, aptamer truncation) and chemical modification of the aptamer and reversal agent (locked nucleic acids) 47, 56 . Further discovery of aptamers against the T-cell markers CD3 and CD4 will also be required to realize a serial selection strategy that can isolate multiple cell subsets tracelessly from a single column. With these advances, aptamer and reversal agentbased isolation approaches could be inexpensively applied in process-engineering strategies to prepare engineered CD4 + and CD8 + T cells through continuous flow methods, thus increasing the accessibility of T-cell immunotherapy.
Methods
Oligonucleotides. All oligonucleotides studied were synthesized by Integrated DNA Technologies. The ssDNA library used in the T-cell−SELEX process was purified using high-performance liquid chromatography and consisted of a 52 bp random sequence flanked by two 18 bp constant regions. The primers used for library amplification between SELEX rounds, with IDT modification codes, are as follows: forward 5′-/56-FAM/ATCCAGAGTGACGCAGCA-3′ and reverse 5′-/5BiosG/ACTAAGCCACCGTGTCCA-3′. The individually synthesized ssDNA aptamers are listed in Supplementary Table 5 .
Antibodies and flow cytometry. The following dyes, antibodies and secondaries were used to stain cells: Zombie Violet (1:500 in 100 μl 10 −6 cells, BioLegend), Zombie Yellow (1:500 in 100 μl 10 −6 cells, BioLegend), APC antihuman CD4 Cell line culture and PBMC isolation. The J.RT3-T3.5 and Jurkat (clone E6-1) cell lines used for counter selection and nucleofection, respectively, were purchased from ATCC. The Epstein−Barr virus-transformed lymphoblastoid cell line (TM-LCL) used in the REP of T cells was made from mononuclear cells as previously described 57 . The CD19 + and OKT3 + K562 cells used for functional assays were generated by lentivirally transducing parental K562 parental cells (ATCC) with CD19-or OKT3-expressing constructs. Raji parental cells were also purchased from ATCC. All the above cell lines were cultured in RPMI 1640 medium (Gibco) with 10% heat-inactivated FBS (Life Tech and VWR). Human PBMCs were isolated from Leukocyte Reduction System cones (Bloodworks Northwest) using Ficoll-Paque density gradient centrifugation (GE). The mixed or CD8 + T cells used in non-isolation experiments were a gift from Juno Therapeutics. Rhesus PBMCs were a gift from A. Taraseviciute (Seattle Children's Research Institute).
Competitive cell−SELEX with T-cell depletion. The SELEX protocol was adapted from a reported method 28 . A schematic of the SELEX procedure is shown in Fig. 1 and the conditions used in the individual rounds are summarized in Supplementary Table 2 . In brief, positive selection was conducted for round 1, in which 4 × 10 7 thawed mixed T cells, depleted of dead cells (Miltenyi), were incubated with 40 nmol of ssDNA library (~10 16 individual sequences) for 1 h at 4 o C in binding buffer. Bound aptamers were extracted and amplified by PCR using Phusion High Fidelity DNA Polymerize (NEB) with forward and reverse primers. Strand separation was performed with High Capacity Neutravidin Agarose Resin (Thermo Scientific), as described previously 28 , and the FAM-labelled ssDNA aptamer pool was used in the next round. For rounds 2−5, the ssDNA aptamer pools were incubated with thawed PBMCs depleted of dead cells, a process termed competitive selection. After three washes, T cells and bound ssDNA sequences were then enriched using a Pan T Cell Isolation Kit (Miltenyi). The ssDNA pool was then extracted and incubated with 10 7 CD3 − CD8 − J.RT3-T3.5 cells at 4 o C as a form of negative selection in each round, and unbound ssDNA sequences were PCR amplified and used to generate ssDNA aptamer pools for use in the sequential round. The wash and binding buffer formulations, as well as folding conditions, are as described previously 28 .
Aptamer binding assays. Cells (2 × 10 5 ) were incubated with 100 μl of folded FAMlabelled ssDNA pools or FAM/biotin-labelled individual aptamers for 20-30 min at 4 o C in binding buffer at the indicated concentrations. For antibody competition and multicolour flow cytometry staining with antibodies, antibodies were added to the primary incubation with aptamer. Cells were washed twice (or three times for large flow panels) in 200 μl of wash buffer supplemented with 1% BSA to remove excess aptamer. If the aptamers or antibodies used were biotinylated, the cells underwent a second incubation with 100 μl of fluorescently labelled streptavidin or neutravidin secondary for 15-20 min at 4 o C in wash buffer with 1% BSA and were washed twice. Stained cells were fixed in 200 μl of wash buffer with 1% BSA and 0.1% PFA before analysis via flow cytometry.
NGS and data analysis. The starting RN and ssDNA pools from each SELEX round were PCR amplified with the barcoded primers listed in Supplementary  Table 3 for sequencing using the MiSeq Reagent Kit v2 (300 cycles) and MiSeq System (Illumina) according to the manufacturer's instructions. Exported FASTA files were analysed with FASTAptamer v1.0.3 29 . Specifically, FASTAptamer-Count was first used to determine rank and reads per million for each sequence, whereafter FASTAptamer-Compare was used to conduct pairwise comparison of reads per million for sequences between adjacent rounds and thus calculated fold enrichment ( Supplementary Table 4 ). Neighbour joining trees were constructed for the top 100 sequences from rounds 2-4 and were further analysed by both FigTree v1.4.3 (tree.bio.ed.ac.uk/software/figtree/) for phylogenetic tree generation and MEME Suite v4.12.0 for motif prediction 31 . The NUPACK web application was used to generate predicted secondary structures of aptamer sequences 58 .
Murine splenocyte isolation and staining. For mouse spleen harvesting, animal work was conducted under protocol no. 4053-01 approved by the Institutional Animal Care and Use Committee at the University of Washington. 20-week-old Tg(Aldh1l1-EGFP,-DTA)D8Rth/J male mice (Jackson Laboratory) were euthanized with avertin and perfused with 20 ml PBS to limit coagulation 59 . Spleens were harvested, minced with scissors and dissociated by sieving over a 40-μm cell strainer (Falcon). Red blood cells were removed by incubation with ACK Lysing Buffer (Gibco) and cells were stained with both anti-mCD3 and anti-mCD8 antibodies and aptamers. siRNA knockdown. Some 10 7 thawed CD8 + T cells were activated with Dynabeads Human T-activator CD3/CD28 (Life Tech) at 1.5 × 10 6 cells ml −1 for 3 d in complete Articles Nature Biomedical eNgiNeeriNg RPMI supplemented with 100 U ml −1 rhIL-2 (Miltenyi, NIBSC calibrated value). On day 3, 3 × 10 6 activated T cells were nucleofected with 50 pmol of both CD8atargeting duplex siRNA 1 and 2, listed in Supplementary Table 6 , or 100 pmol of scrambled duplex siRNA (IDT) using the Human T Cell Nucleofector Kit (Lonza) with Program T-023 according to the manufacturer's instructions. Aptamer and anti-CD8 antibody staining, as discussed in the previous section, were performed 24 h later and analysed via flow cytometry.
Plasmid transfection. CD8a-hnRNP-M-EGFP was a gift from L. Lu (Addgene plasmid no. 86054) 60 . 2 × 10 6 CD8 − Jurkat cells were nucleofected (Lonza) with 2 μg of the plasmid using the Nucleofector Kit V (Lonza) with Program X-001 according to the manufacturer's instructions. The cells were analysed 24 h later for both GFP expression and anti-CD8 antibody and aptamer binding via flow cytometry.
BLI. BLI studies were conducted on a FortéBio Octet Red96 instrument at 25 o C with sample agitation at 1,000 r.p.m. The sample buffer used for all steps comprised binding buffer with 0.01% Tween 20. Streptavidin-coated biosensors were loaded with 50 nM biotinylated aptamer until all sensors (except for the reference) reached a capture threshold of 0.5 nm. After a 100 s rinse and baseline steps in buffer alone, sensors were exposed to a 1:3 dilution series of recombinant human CD8a protein (Sino Biological) ranging from 150 to 5.56 nM. Association with protein was monitored for 1,200 s and dissociation was carried out for 600 s in buffer alone. Data analysis was carried out using Octet Data Analysis 9.0 (FortéBio). Kinetic constants were calculated by conducting a global fit of the several processed association and dissociation curves from the protein dilution series to a 1:1 binding model. The quality of the fit was evaluated using R 2 and χ 2 values.
Comparison to previously reported aptamer. CD8Ap17s, as described by Wang et al. 42 , was synthesized with the sequence 5′-CTACAGCTTGCTATGCTCCCCTTGGGGTA/iSp18//3Bio/-3′. Binding to CD8 + T cells was compared to our aptamer A3t ( Supplementary Table 5 ), and CD8Ap17s binding buffer (A-BB) and folding conditions were used in addition to our binding buffer (T-BB) and folding conditions. For the CD8Ap17s conditions, 1 μM of each aptamer was folded by denaturation at 95 o C for 5 min and cooled to 37 o C in its wash buffer (40 mM HEPES, 150 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 1 mM CaCl 2 , pH 7.5). Binding was similarly carried out and analysed as detailed above but in CD8Ap17s binding buffer, which comprised the wash buffer supplemented with 5% FBS.
Reversal agent optimization. A 36 bp reversal agent was designed complementary to the 3′ end of aptamer A3t (Supplementary Table 5 ). Binding to CD8 + T cells with 5 nM aptamer A3t was first carried out with secondary fluorescent streptavidin labelling, as discussed above. Labelled cells were then incubated with varying fold excesses (over the amount of aptamer used) of 200 μl of reversal agent in wash buffer with 1% BSA for different times and temperatures. Cells were washed twice with the wash buffer with 1% BSA to remove eluted aptamers, fixed and analysed via flow cytometry.
Traceless selection of CD8 + T cells from PBMCs. For each PBMC donor, 200 μl of Anti-Biotin Microbeads (Miltenyi) were diluted to 1,000 μl in binding buffer with 5 nM aptamer A3t and incubated for 15 min at 4 o C under gentle rotation. The aptamer-labelled bead suspensions were then added to 2 × 10 8 Ficoll-isolated PBMCs and allowed to incubate for another 15 min at 4 o C under gentle rotation. Cells were subsequently washed with 10 ml of autoMACS Rinsing Solution (Miltenyi) supplemented with 0.5% BSA, resuspended in the same buffer and applied over two LS columns in parallel on a QuadroMACS separator (Miltenyi) according to the manufacturer's instructions. A flow-through fraction, which includes the flow through from the initial application of cells and the three subsequent 3 ml column washes, was collected. Afterwards, 1 ml of 500 nM reversal agent (100-fold excess) in autoMACS solution with 0.5% BSA and 5 mM MgCl 2 was applied to the column on the magnet containing cells labelled with aptamer-functionalized microbeads. Approximately 600-700 μl of the reversal agent solution passed through the column before it was plugged with a M/F Luer Lock Plug (Smiths Medical) for a 10 min incubation at room temperature. On removal of the plug, the column was washed three times with 3 ml of autoMACS solution with 0.5% BSA and 5 mM EDTA, which constituted the RAE fraction. The RAE cells were immediately spun down and resuspended in fresh buffer to remove any reversal agent. Remaining cells on the column were removed with a column flush according to the manufacturer's instructions. In parallel, CD8 + cells from the same donor were isolated from 200 × 10 6 PBMCs in the column flush fraction with antibody-based CD8 Microbeads (Miltenyi), according to the manufacturer's instructions.
All fractions were counted and analysed via flow cytometry with two antibody panels: a yield panel staining for CD3, CD8 and CD16 expression; and a phenotype panel staining for CD3, CD4, CD8, CD45RA, CD45RO, CCR7 and CD62L expression. Furthermore, 10 6 cell pellets from both the antibody-isolated column flush fraction and aptamer-isolated RAE fraction were flash frozen on dry ice and ethanol for NanoString nCounter analysis. The remaining cells were banked for downstream CAR T-cell production.
CD19 CAR T-cell manufacturing. CD8 + T cells from both isolation methods from each donor were thawed and 3.3 × 10 6 cells for both mock and CD19 CAR T-cell groups were stimulated 1:1 with Dynabeads Human T-Activator CD3/ CD28 (Invitrogen) in 4 ml complete RPMI with 50 U ml −1 rhIL-2 (Miltenyi) and 0.5 ng ml −1 rhIL-15 (Miltenyi) in a 12-well plate. After 2 d (S1D2), cells designated for CAR T-cell production were transduced with clinical-grade PLAT-02 CD19 CAR lentiviral vector (a gift from the City of Hope) at a multiplicity of infection of 0.3 with 40 μg ml −1 protamine sulphate via spinoculation for 30 min at 800g at 32 o C. Thereafter, media exchanges were conducted every 2-3 d to replenish cytokines and cells were moved to larger culture vessels when cell concentrations reached 1.5-2 × 10 6 cells ml −1 . The activator beads were removed 9 d poststimulation, termed S1D9, and cells were stained for EGFRt surrogate marker expression to assess transduction efficiency. CAR + cells were magnetically enriched 12 d poststimulation (S1D12) using biotinylated Erbitux antibody and Anti-Biotin Microbeads according to the manufacturer's instructions. On day 14 poststimulation (S1D14), cells were analysed via flow cytometry by staining for: activation/proliferation with Ki-67; exhaustion/activation with PD1, TIM3 and LAG3; and differentiation with CD62L and CD45RA.
The two-week-stimulated T cells were further expanded using a two week REP, as previously described 61 . Briefly, 1.5 × 10 6 CD19 CAR T cells were co-incubated with 10.5 × 10 6 irradiated CD19 + TM-LCL feeder cells in 25 ml of complete RPMI supplemented with the aforementioned cytokine concentrations in T-25 flasks (Corning). Similarly, 1.5 × 10 6 mock T cells were co-incubated with 10 × 10 6 irradiated CD19 + TM-LCL feeder cells and 50 × 10 6 irradiated donor-mismatched PBMC feeder cells in 25 ml complete RPMI supplemented with the same cytokines and 30 ng ml −1 OKT3 in T-25 flasks (Corning). PBMCs and TM-LCL cells were irradiated at 3,500 and 8,000 rad, respectively, using a caesium source irradiator. Cells were maintained as for the two week activator bead expansion, except that OKT3 was replaced only on day 2. On day 13 after the REP (S1R1D13), the CD19 CAR T cells were stained for EGFRt surrogate transduction marker expression to assess the enrichment and purity of the CAR + cells after magnetic selection and the REP. On day 14 after the REP (S1R1D14), the cells were characterized again for differentiation and a 10 6 cell pellet of each cell lot was flash frozen for downstream NanoString nCounter analysis. The remaining cells were used for in vitro functional assays or banked for in vivo studies.
NanoString nCounter gene profiling. Thawed cell pellets were resuspended in RLT lysis buffer with β-mercaptoethanol at 3,500 cells μl −1 and overnight hybridization reactions with the nCounter Immunology Panel (Human V2) Reporter CodeSet and Capture ProbeSet were run according to the manufacturer's instructions. Samples were run on the nCounter SPRINT Profiler (NanoString) and mRNA counts were normalized in groups by day and cell type (D0, S1R1D14 mocks, S1R1D14 CD19 CAR) using nSolver 4.0 (NanoString) and Advanced Analysis 2.0 (NanoString), which selects the housekeeping genes that minimize the pairwise variation statistic. Each group has six samples: three biological replicates for antibody-based isolation and three biological replicates for aptamer-based isolation. Using Excel (Microsoft), mRNA probes that gave normalized counts of less than 25 for more than 50% of the samples in a group (four or more samples) were removed from the analysis as they were mostly below the background. The unadjusted P values of the log 2 fold changes in the probe counts of aptamer-isolated cells over antibody-isolated cells were determined using a paired two-tailed t-test in Excel and the threshold for significance was calculated using the Benjamini−Yekutieli multiple-testing correction in R software v3.3.2 (http://www.R-project.org/). Antitumour cytotoxicity assay. K562 + OKT3, K562 + CD19 and Raji parental target cells were each seeded at 5 × 10 6 cells in 4 ml of complete RPMI in a well of a 12-well plate and 75 μl of Cr-51 (PerkinElmer) was added to each well with cells. Cells were harvested a day later and seeded at 5 × 10 3 cells per well in a 96-well plate at 100 μl. S1R1D14 CD8 + mock and CD19 CAR effector T cells in 100 μl were added to the target cells at different effector-to-target ratios ranging from 1:1 to 30:1. Media without cells or with 2% SDS were also added to wells with target cells as minimum and maximum lysis controls, respectively. Target and effector cell mixtures were lightly pelleted at 700 r.p.m. for 2 min before incubating for 4 h at 37 o C in an incubator. 50 μl of supernatant was then harvested into LUMA plates (PerkinElmer) and allowed to dry overnight. The plates were analysed by a TopCount NXT Microplate Scintillation and Luminescence Counter (PerkinElmer).
Antitumour cytokine release assay. K562 + OKT3, K562 + CD19 and Raji parental target cells were plated at 5 × 10 4 cells per well in a 96-well plate at 100 μl. S1R1D14 CD8 + mock and CD19 CAR effector T cells were added to target cells at 10 5 cells per well in 100 μl and allowed to co-incubate for 24 h. Cells were then pelleted at 1,200 r.p.m. for 3 min and 120 μl of supernatant was collected and frozen at −80 o C until ready to analyse. Thawed supernatants were diluted 1:5 or 1:20 in RPMI without FBS, and IL-2, IFN-γ and TNF-α in the supernatants and a standard (Bio-Rad) were captured and fluorescently detected on magnetic beads using a 3-plex Bio-Plex custom kit with flat magnetic plates (Bio-Rad) according to the manufacturer's instructions. The beads with captured cytokines were analysed using a Bio-Plex 200 system (Bio-Rad). 
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